Equities

Hemostemix Inc

Hemostemix Inc

Actions
  • Price (CAD)0.04
  • Today's Change0.005 / 14.29%
  • Shares traded43.00k
  • 1 Year change-75.00%
  • Beta0.4426
Data delayed at least 15 minutes, as of May 02 2024 20:18 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Hemostemix Inc. is a Canada-based autologous stem cell therapy company. The Company has developed, patented, and is scaling a patient’s blood-based stem cell therapeutics platform, which includes angiogenic cell precursors, neuronal cell precursors and cardiomyocyte cell precursors. The Company holds 87 patents on the derivation of three stem cell lineages from the patient’s blood, including angiogenic cell precursors (ACP-01), neuronal cell precursors, and cardiomyocyte cell precursors. ACP-01, its lead clinical-stage candidate, is an autologous cell therapy for the treatment of critical limb ischemia. ACP-01 is in a Phase 2 clinical trial in Canada and the United States. Its technology includes methods for collecting the synergetic cell population and manufacturing a personalized regenerative therapy that can be administered to a patient within seven days of the initial cell collection. Its subsidiaries include Kwalata Trading Limited, Hemostemix Ltd. and PreCerv Inc.

  • Revenue in CAD (TTM)0.00
  • Net income in CAD-2.50m
  • Incorporated2014
  • Employees--
  • Location
    Hemostemix IncSuite 730; 1015 - 4 St SWCALGARY T2R 1J4CanadaCAN
  • Phone+1 (647) 919-8820
  • Fax+1 (403) 818-7672
  • Websitehttps://hemostemix.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Intellipharmaceutics International Inc1.24m-4.34m2.63m33.00------2.13-0.1311-0.13110.0374-0.53190.6027--3.37---211.39-132.15-----88.96---350.72-499.37---19.36-------58.7543.78------
Radient Technologies Inc3.15m-11.30m2.69m33.00------0.8548-0.0216-0.02160.006-0.02780.11081.566.00---39.76-67.36---118.27-3.911.66-359.00-534.110.0251-3.58----45.4965.3069.41--200.33--
Lifeist Wellness Inc21.66m-14.13m2.94m72.00--0.8063--0.1358-0.0287-0.02870.04510.00621.273.327.94---82.93-62.71-158.05-78.8130.6617.06-65.22-136.110.4707-257.620.268---1.85--24.45------
Entourage Health Corp39.46m-116.92m3.05m251.00------0.0774-0.3807-0.38070.1285-0.42150.49541.798.08---146.79-46.15---74.686.12-53.10-296.29-214.310.0992-1.136.15---3.2694.98-56.01---13.82--
Hemostemix Inc0.00-2.50m3.47m-----------0.0303-0.03030.00-0.08460.00-------642.29-599.98---------------3.99--------52.21------
Eve & Co Inc7.77m-5.92m3.76m--------0.4836-0.2055-0.20550.26980.7330.15190.74938.73---11.58---24.24---3.10---76.22--0.062-5.050.4892--2.94---71.97------
Innovotech Inc1.18m-157.59k3.88m16.00--4.19--3.28-0.004-0.0040.03040.02390.96966.625.51---12.922.90-15.523.5668.6371.56-13.332.192.82--0.00--5.057.42-15.43--35.69--
Appili Therapeutics Inc1.15m-5.34m4.22m8.00------3.67-0.044-0.0440.0095-0.08110.5047--2.12---234.31-117.41---173.66-----464.23-3,037.15---5.32-----75.97--63.20---43.04--
Data as of May 02 2024. Currency figures normalised to Hemostemix Inc's reporting currency: Canadian Dollar CAD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.